Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eryaspase for ALL Patients with PEG-Asparaginase Hypersensitivity
NCT03267030Phase 2Completed
- Start
- Aug 2017
- Primary completion
- Aug 2020
- Modality
- Replacement Enzymes
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of eryaspase in acute lymphoblastic leukemia (ALL). Primary endpoint: Pharmacokinetics ASNase Activity >100 U/L at 14 Days. Started Aug 2017; status: completed.
02
Drugs
eryaspase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03267030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03267030.